Prioritize Cognitive-Behavioral Therapy for Insomnia (CBT-I) and Consider Switching from Zaleplon to a Medication Targeting Sleep Maintenance

Given your chronic post-stroke insomnia with persistent sleep-onset latency, early morning awakenings, and highly variable sleep duration despite high-dose zaleplon (15–20 mg, which exceeds the FDA-studied 10 mg dose), you should immediately pursue formal CBT-I as first-line therapy and consider transitioning to a medication that addresses sleep maintenance insomnia, such as low-dose doxepin (3–6 mg) or suvorexant, rather than continuing to escalate a drug designed primarily for sleep onset. 1, 2, 3

Why CBT-I Must Be Your Foundation

The most recent and authoritative guidelines—including the 2021 American Academy of Sleep Medicine (AASM) behavioral guideline 3 and the 2016 American College of Physicians (ACP) guideline 4—strongly recommend CBT-I as the initial intervention for chronic insomnia in adults. This is a Standard/Strong recommendation based on robust evidence showing sustained benefit beyond medication alone 1, 3.

CBT-I includes: stimulus control therapy, sleep restriction therapy, cognitive therapy, and relaxation strategies—all of which you've partially engaged with (relaxation techniques), but a structured, multicomponent program delivered by a trained provider is far more effective than piecemeal self-management 1, 3.
Why it matters for you: Your insomnia is comorbid with stroke (2003), making it secondary/comorbid insomnia. Guidelines explicitly state that CBT-I is effective for both primary and comorbid insomnia, including in older adults and chronic hypnotic users 1, 5. Your stroke history does not exclude you—it makes behavioral intervention even more critical to avoid long-term medication dependence 6.
Delivery options: If in-person access is limited, internet-based CBT-I programs are conditionally recommended and may improve adherence for a busy professional like yourself 3.

Common pitfall: Many clinicians and patients view CBT-I as "too time-consuming" or "not as effective as pills." This is incorrect. Meta-analyses show CBT-I produces durable improvements in sleep latency, wake after sleep onset, and total sleep time—often superior to pharmacotherapy alone in the long term 1, 5, 3.

Your Current Medication Regimen: Zaleplon Is the Wrong Tool for Your Problem

Zaleplon's Limitations

Zaleplon (Sonata) is FDA-approved only for sleep-onset insomnia at a 10 mg dose 2, 7. Clinical trials show:

Efficacy is limited to reducing sleep latency (time to fall asleep), with no consistent benefit for sleep maintenance or total sleep time 7.
The 20 mg dose showed slightly greater effect on sleep onset than 10 mg, but you are taking 15–20 mg and still experiencing 35–40 minute sleep latency—suggesting tolerance or inadequate response 7.
Zaleplon's ultra-short half-life (~1 hour) means it is cleared rapidly, offering no coverage for middle-of-the-night or early morning awakenings (your 4–5 AM wake time) 7.

Your Symptom Pattern Demands a Different Approach

Your insomnia is characterized by:

Moderate sleep-onset latency (35–40 minutes): Zaleplon should address this, but it's not working adequately.
Early morning awakenings (4–5 AM): Zaleplon provides zero benefit for this 7.
Variable sleep duration (0–7.5 hours): This suggests sleep maintenance insomnia, not just sleep-onset difficulty.

The 2017 AASM pharmacologic guideline 2 explicitly recommends:

For sleep-onset insomnia: Zaleplon, ramelteon, or triazolam (weak recommendations).
For sleep maintenance insomnia: Suvorexant, low-dose doxepin, eszopiclone, zolpidem, or temazepam (weak recommendations).
For both sleep onset AND maintenance: Eszopiclone, zolpidem, or temazepam (weak recommendations).

You need a medication that addresses sleep maintenance, not just onset.

Recommended Pharmacologic Adjustments

Option 1: Switch to Low-Dose Doxepin (3–6 mg) – Preferred for Sleep Maintenance

Low-dose doxepin (Silenor) is FDA-approved specifically for sleep maintenance insomnia and is recommended by the 2017 AASM guideline 2.

Mechanism: Selective H1-histamine receptor antagonist at low doses (3–6 mg), promoting sleep continuity without significant anticholinergic or cardiac effects seen at higher antidepressant doses 2, 8, 9.
Evidence: Improves wake after sleep onset (WASO) and total sleep time, with minimal next-day sedation due to its ~15-hour half-life 2, 8, 9.
Dosing: Start 3 mg nightly, 30 minutes before bed. May increase to 6 mg if needed 2, 9.
Safety: Well-tolerated in older adults; avoid in patients with severe urinary retention or narrow-angle glaucoma 9.

Why this is ideal for you: Your early morning awakenings (4–5 AM) and variable sleep duration suggest inadequate sleep maintenance. Doxepin's longer half-life provides coverage through the night without causing morning grogginess in most patients 9.

Option 2: Suvorexant (Dual Orexin Receptor Antagonist) – Targets Wakefulness, Not Sedation

Suvorexant (Belsomra) is FDA-approved for sleep-onset and sleep-maintenance insomnia and represents a mechanistically distinct approach 2.

Mechanism: Blocks orexin receptors (OX1R and OX2R), which promote wakefulness. Unlike GABAergic drugs (zaleplon, benzodiazepines), suvorexant inhibits wakefulness rather than inducing sedation 10, 8, 9.
Evidence: Improves both sleep latency and WASO, with sustained efficacy over 12 months and no evidence of rebound insomnia, withdrawal, or abuse potential 2, 10, 8.
Dosing: Start 10 mg nightly (5 mg in elderly or those on CYP3A4 inhibitors). May increase to 20 mg if needed 2, 10.
Safety: Most common side effect is next-day somnolence (dose-dependent). Avoid in narcolepsy 10, 9.

Why this is ideal for you: Suvorexant addresses both sleep onset and maintenance, and its unique mechanism avoids the tolerance and dependence risks associated with chronic benzodiazepine receptor agonist use 10, 8. Given your 20+ years of zaleplon use, switching to a non-GABAergic agent may restore efficacy 8.

Option 3: Eszopiclone (Lunesta) – If You Prefer a Benzodiazepine Receptor Agonist

Eszopiclone is FDA-approved for both sleep-onset and sleep-maintenance insomnia and has a longer half-life (~6 hours) than zaleplon 2, 8.

Dosing: Start 2 mg nightly (1 mg in elderly). May increase to 3 mg if needed 2.
Evidence: Improves sleep latency, WASO, and total sleep time 2, 8.
Caution: Like zaleplon, eszopiclone is a benzodiazepine receptor agonist and carries risks of tolerance, dependence, and next-day impairment—especially in older adults 5, 8. Given your long-term zaleplon use, cross-tolerance may limit benefit.

This is a fallback option if doxepin or suvorexant are not tolerated.

Gabapentin: Reassess Its Role

You are taking extended-release gabapentin 600 mg for sleep. The 2008 AASM guideline 1 lists gabapentin as a last-line option for insomnia, suitable primarily when treating comorbid conditions (e.g., neuropathic pain, restless legs syndrome).

Evidence for insomnia is weak: Gabapentin is not FDA-approved for insomnia, and the 2017 AASM pharmacologic guideline 2 does not recommend it due to insufficient data 1, 8.
If you have no comorbid pain or RLS, consider tapering gabapentin under supervision, as it may contribute to daytime sedation or cognitive dulling without clear sleep benefit 8.

Non-Pharmacologic Interventions: Beyond Relaxation

Stimulus Control Therapy (Critical for Your 35–40 Minute Sleep Latency)

You report taking sleep aids "once in bed" and experiencing 35–40 minutes to fall asleep. Stimulus control is a cornerstone of CBT-I and directly addresses conditioned arousal in bed 1, 5, 3.

Key rules:

Go to bed only when sleepy (not at a fixed time like 9:30 PM if you're not drowsy).
Use the bed only for sleep and sex—no reading, TV, or phone use in bed.
If you cannot fall asleep within 15–20 minutes, get out of bed and return only when sleepy. Repeat as needed 5, 3.
Wake at the same time every morning (even after a poor night's sleep) to stabilize your circadian rhythm 5.

Why this matters: Your history of "disorganized behavior" when taking sleep aids before bed suggests you may be lying in bed awake, which reinforces the association between bed and wakefulness 3. Stimulus control breaks this cycle.

Sleep Restriction Therapy (For Variable Sleep Duration)

Your sleep varies wildly (0–7.5 hours). Sleep restriction therapy consolidates sleep by limiting time in bed to match actual sleep time, then gradually increasing it as sleep efficiency improves 1, 3.

Example protocol:

Calculate your average total sleep time over 1 week (e.g., 5 hours).
Restrict time in bed to 5 hours (e.g., 12:30 AM–5:30 AM).
Once sleep efficiency reaches ≥85%, increase time in bed by 15–30 minutes.
Repeat until you achieve 7–8 hours of consolidated sleep 3.

Caution: Sleep restriction can cause transient daytime sleepiness. Avoid if you have a seizure disorder, bipolar disorder, or safety-sensitive job (e.g., driving) 3. Discuss with your provider.

Address Circadian Rhythm Disruption (Post-Stroke Consideration)

Emerging evidence suggests stroke can disrupt the suprachiasmatic nucleus (SCN), the brain's circadian pacemaker, leading to fragmented sleep and early morning awakenings 6, 11.

Strategies to strengthen circadian rhythms:

Bright light exposure (10,000 lux) for 30 minutes upon waking (e.g., 5 AM) to anchor your circadian clock 5.
Avoid bright light (especially blue light from screens) after 8 PM to promote melatonin secretion 5.
Consider timed melatonin (0.5–3 mg, 2 hours before desired bedtime) if circadian misalignment is suspected, though evidence for chronic insomnia is weak 2, 8.

Practical Implementation Algorithm

Step 1: Initiate or Intensify CBT-I (Immediately)

Refer to a behavioral sleep medicine specialist or enroll in an evidence-based digital CBT-I program (e.g., Sleepio, SHUTi) 3.
Implement stimulus control and sleep restriction as outlined above.

Step 2: Adjust Pharmacotherapy (Within 1–2 Weeks)

Taper zaleplon (e.g., reduce by 5 mg every 3–7 days) while starting:
- Low-dose doxepin 3 mg (preferred for sleep maintenance) OR
- Suvorexant 10 mg (if you prefer a non-sedating, non-GABAergic option).
Reassess gabapentin's necessity. If no comorbid pain/RLS, consider tapering (reduce by 100–200 mg every 3–7 days) 8.

Step 3: Optimize Sleep Hygiene and Circadian Anchors

Fixed wake time (e.g., 5 AM daily), even on weekends.
Bright light exposure at 5 AM (30 minutes).
Avoid caffeine after 12 PM and alcohol within 3 hours of bedtime 5.
Limit time in bed to actual sleep time (sleep restriction).

Step 4: Monitor and Adjust (Every 2–4 Weeks)

Track sleep latency, WASO, total sleep time, and daytime function using a sleep diary or wearable device.
If doxepin 3 mg is insufficient after 2 weeks, increase to 6 mg 2, 9.
If suvorexant 10 mg is insufficient after 2 weeks, increase to 20 mg 2, 10.
If no improvement after 4–6 weeks, consider combination therapy (e.g., suvorexant + CBT-I) or re-evaluate for occult comorbidities (e.g., sleep apnea, restless legs syndrome, depression) 1, 5.

Critical Pitfalls to Avoid

Do not continue escalating zaleplon. You are already above the FDA-studied dose (10 mg), and further increases will not address your sleep maintenance problem 7.
Do not rely on gabapentin without a clear indication. Off-label use for insomnia lacks strong evidence and may cause unnecessary side effects 1, 8.
Do not skip CBT-I. Medication alone is insufficient for chronic insomnia and increases the risk of long-term dependence 1, 4, 3.
Do not take sleep medications with food. High-fat meals delay zaleplon absorption by ~2 hours and reduce peak concentration by 35%, blunting efficacy 7. Take on an empty stomach, at least 2 hours after dinner.
Do not ignore early morning awakenings. This is a hallmark of sleep maintenance insomnia and circadian disruption, requiring a medication with a longer half-life (doxepin, suvorexant) or circadian interventions (bright light, timed melatonin) 2, 9, 6.

Special Considerations for Post-Stroke Insomnia

Your stroke history (2003) is relevant. Post-stroke insomnia is common and multifactorial, involving injury to sleep-wake regulatory networks, circadian disruption, and neuroinflammation 6. Recent research suggests:

Zolpidem (another benzodiazepine receptor agonist) may improve post-stroke sleep by restoring SCN activity 11, but this does not justify continuing zaleplon, which is less effective for sleep maintenance.
Suvorexant's orexin-blocking mechanism may be particularly beneficial post-stroke, as orexin dysregulation is implicated in post-stroke insomnia 6.

Bottom line: Your stroke history does not change the recommendation to prioritize CBT-I and switch to a sleep-maintenance medication, but it underscores the importance of addressing circadian and neurobiological factors 6, 11.

Summary of Recommendations

Intervention	Action	Rationale
CBT-I	Initiate immediately (in-person or digital)	Standard recommendation for chronic insomnia; effective for comorbid insomnia [1,4,3]
Zaleplon	Taper and discontinue	Ineffective for sleep maintenance; you are above FDA-studied dose [2,7]
Low-dose doxepin 3–6 mg	Start as replacement for zaleplon	FDA-approved for sleep maintenance; addresses early morning awakenings [2,9]
Suvorexant 10–20 mg	Alternative to doxepin	Non-GABAergic; addresses sleep onset and maintenance; no tolerance/dependence [2,10,8]
Gabapentin 600 mg ER	Reassess necessity; consider taper if no comorbid pain/RLS	Weak evidence for insomnia; may cause unnecessary side effects [1,8]
Stimulus control	Implement strict rules (out of bed if not asleep in 15–20 min)	Breaks conditioned arousal; reduces sleep latency [1,3]
Sleep restriction	Limit time in bed to actual sleep time	Consolidates sleep; improves sleep efficiency [1,3]
Bright light therapy	10,000 lux for 30 min at 5 AM	Anchors circadian rhythm; addresses early morning awakenings [5,6]

Your next step: Schedule an appointment with a sleep medicine specialist or behavioral sleep medicine provider to initiate CBT-I and discuss transitioning from zaleplon to low-dose doxepin or suvorexant. Do not continue your current regimen—it is not addressing your core problem (sleep maintenance insomnia) and may perpetuate dependence on an ineffective medication 1, 2, 3.

Have a follow-up question?